Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;32(1):193-197.
doi: 10.1007/s00198-020-05498-7. Epub 2020 Jul 14.

Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients

P V-Q Nguyen  1   2 , M Bouin  3 , L G Ste-Marie  3
Affiliations

Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients

P V-Q Nguyen et al. Osteoporos Int. 2021 Jan.

Abstract

Oral bisphosphonates are effective medications for the prevention of fractures in people suffering from osteoporosis. They are associated with gastrointestinal adverse reactions the most severe being an esophageal ulcer. It is unclear if oral bisphosphonates have a similar gastrointestinal safety profile in the hospital setting as in the community setting because hospitalized patients are often bedridden which may hinder proper drug administration.

Introduction: To evaluate the incidence of upper gastrointestinal symptoms in hospitalized patients taking oral bisphosphonate.

Methods: This single-center prospective cohort study included hospitalized adult patients actively taking risedronate or alendronate. Upper gastrointestinal symptoms were actively assessed at the baseline and 1 to 5 h following the administration of the oral bisphosphonate.

Results: A total of 298 patients were included in the study. The mean age was 64 ± 15 years. During the follow-up period, gastric and esophageal symptoms affected 32 patients (10.7%). Epigastric burning, dysphagia, and regurgitation were reported in 4.4% (n = 13), 3% (n = 9), 2.7 (n = 8), and 2.3% (n = 7) patients, respectively. Heartburn, retro-sternal pain, and odynophagia were observed in 1.7% (n = 5), 1.7% (n = 5), and 0.3% (n = 1) patients.

Conclusion: The incidence of adverse reaction was similar to that reported in community trials. The administration of oral bisphosphonate in hospitalized patients does not represent an additional risk for upper gastrointestinal adverse events. Treatment should be optimized during the hospital stay to improve the pharmacological management of osteoporosis.

Keywords: Adverse drug reaction; Bisphosphonate; Osteoporosis; Upper gastrointestinal events.

PubMed Disclaimer

References

    1. Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38:S4–S9 - DOI
    1. Golob AL, Laya MB (2015) Osteoporosis: screening, prevention, and management. Med Clin North Am 99:587–606 - DOI
    1. Khan A, Fortier M, Menopause, et al. (2014) Osteoporosis in menopause. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 36:839–840
    1. Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43 - DOI
    1. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 11:83–91

LinkOut - more resources